Patents by Inventor Kevin Richard Guertin

Kevin Richard Guertin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aminomethyl quinolone compounds
    Patent number: 8501732
    Abstract: The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: August 6, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Joseph A. Bilotta, Adrian Wai-Hing Cheung, Fariborz Firooznia, Kevin Richard Guertin, Stuart Hayden, Nancy-Ellen Haynes, Christine M. Lukacs-Lesburg, Nicholas Marcopulos, Eric Mertz, Lida Qi, Yimin Qian, Sung-Sau So, Jenny Tan, Kshitij C. Thakkar
  • Adamantyl compounds
    Patent number: 8471027
    Abstract: The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: June 25, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Adrian Wai-Hing Cheung, Kevin Richard Guertin, Nancy-Ellen Haynes, Eric Mertz, Lida Qi, Yimin Qian, Nathan Robert Scott
  • AMINOMETHYL QUINOLONE COMPOUNDS
    Publication number: 20130018043
    Abstract: The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.
    Type: Application
    Filed: July 11, 2012
    Publication date: January 17, 2013
    Inventors: Joseph A. Bilotta, Adrian Wai-Hing Cheung, Fariborz Firooznia, Kevin Richard Guertin, Stuart Hayden, Nancy-Ellen Haynes, Christine M. Lukacs-Lesburg, Nicholas Marcopulos, Eric Mertz, Lida Qi, Yimin Qian, Sung-Sau So, Jenny Tan, Kshitij C. Thakkar
  • ADAMANTYL COMPOUNDS
    Publication number: 20120258982
    Abstract: The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.
    Type: Application
    Filed: April 3, 2012
    Publication date: October 11, 2012
    Inventors: Adrian Wai-Hing Cheung, Kevin Richard Guertin, Nancy-Ellen Haynes, Eric Mertz, Lida Qi, Yimin Qian, Nathan Robert Scott
  • GPR119 receptor agonists
    Patent number: 8188098
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: May 29, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Shawn David Erickson, Paul Gillespie, Kevin Richard Guertin, Prabha Saba Karnachi, Kyungjin Kim, Chun Ma, Warren William McComas, Sherrie Lynn Pietranico-Cole, Lida Qi, Jefferson Wright Tilley, Qiang Zhang
  • Substituted thiazolo[5,4-d]pyrimidine urea derivatives
    Patent number: 7947692
    Abstract: There are presented compounds of the formula or a pharmaceutically acceptable salt thereof, which are active adenosine A2B receptor antagonists and useful in the treatment of diabetes, diabetic retinopathy, asthma and diarrhea.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: May 24, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: John A. Brinkman, Adrian Wai-Hing Cheung, Fariborz Firooznia, Kevin Richard Guertin, Nicholas Marcopulos, Lida Qi, Jagdish Kumar Racha, Ramakanth Sarabu, Jenny Tan, Jefferson Wright Tilley
  • Inhibitors of 11?-Hydroxysteroid Dehydrogenase
    Patent number: 7790711
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.
    Type: Grant
    Filed: July 14, 2008
    Date of Patent: September 7, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Paul Gillespie, Kevin Richard Guertin, Lida Qi, Qiang Zhang
  • Adamantyl-pyrazole carboxamides as inhibitors of 11?-hdroxysteroid dehydrogenase
    Patent number: 7728029
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.
    Type: Grant
    Filed: March 14, 2007
    Date of Patent: June 1, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kevin William Anderson, Nader Fotouhi, Paul Gillespie, Robert Alan Goodnow, Jr., Kevin Richard Guertin, Nancy-Ellen Haynes, Michael Paul Myers, Sherrie Lynn Pietranico-Cole, Lida Qi, Pamela Loreen Rossman, Nathan Robert Scott, Kshitij Chhabilbhai Thakkar, Jefferson Wright Tilley, Qiang Zhang
  • Pyrazolones as inhibitors of 11?-hydroxysteroid dehydrogenase
    Patent number: 7622492
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.
    Type: Grant
    Filed: August 18, 2006
    Date of Patent: November 24, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bruce Lester Banner, Joseph Anthony Bilotta, Nader Fotouhi, Paul Gillespie, Robert Alan Goodnow, Jr., Matthew Michael Hamilton, Nancy-Ellen Haynes, Agnieszka Kowalczyk, Alexander Mayweg, Michael Paul Myers, Sherrie Lynn Pietranico-Cole, Nathan Robert Scott, Kshitij Chhabilbhai Thakkar, Jefferson Wright Tilley, Kevin Richard Guertin
  • GPR119 Receptor Agonists
    Publication number: 20090286812
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
    Type: Application
    Filed: May 1, 2009
    Publication date: November 19, 2009
    Inventors: Shawn David Erickson, Paul Gillespie, Kevin Richard Guertin, Prabha Saba Karnachi, Kyungjin Kim, Chun Ma, Warren William McComas, Sherrie Lynn Pietranico-Cole, Lida Qi, Jefferson Wright Tilley, Qiang Zhang
  • Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase
    Publication number: 20090023709
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.
    Type: Application
    Filed: July 14, 2008
    Publication date: January 22, 2009
    Inventors: Paul Gillespie, Kevin Richard Guertin, Lida Qi, Qiang Zhang
  • Substituted N-acyl-2-aminothiazoles
    Patent number: 7407977
    Abstract: There are presented compounds of the formula or a pharmaceutically acceptable salt thereof, which are useful in the treatment of diabetes, diabetic retinopathy, asthma and diarrhea.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: August 5, 2008
    Assignee: Hoffman-La Roche Inc.
    Inventors: Jianping Cai, Adrian Wai-Hing, Fariborz Firooznia, Kevin Richard Guertin, Lida Qi
  • Thiazolo-pyrimidine/pyridine urea derivatives
    Publication number: 20070270433
    Abstract: There are presented compounds of the formula or a pharmaceutically acceptable salt thereof, which are active adenosine A2B receptor antagonists and useful in the treatment of diabetes, diabetic retinopathy, asthma and diarrhea.
    Type: Application
    Filed: May 11, 2007
    Publication date: November 22, 2007
    Inventors: John A. Brinkman, Adrian Wai-Hing Cheung, Fariborz Firooznia, Kevin Richard Guertin, Nicholas Marcopulos, Lida Qi, Jagdish Kumar Racha, Ramakanth Sarabu, Jenny Tan, Jefferson Wright Tilley
  • Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase
    Publication number: 20070225280
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.
    Type: Application
    Filed: March 14, 2007
    Publication date: September 27, 2007
    Inventors: Kevin William Anderson, Nader Fotouhi, Paul Gillespie, Robert Alan Goodnow, Kevin Richard Guertin, Nancy-Ellen Haynes, Michael Paul Myers, Sherrie Lynn Pietranico-Cole, Lida Qi, Pamela Loreen Rossman, Nathan Robert Scott, Kshitij Chhabilbhai Thakkar, Jefferson Wright Tilley, Qiang Zhang
  • Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
    Patent number: 7138529
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4 and n are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the antagonism of the glucagon receptor, such as diabetes.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: November 21, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Shawn David Erickson, Paul Gillespie, Kevin Richard Guertin
  • 5-substituted-six-membered heteroaromatic glucokinase activators
    Patent number: 7132425
    Abstract: The present invention provides a compound according to formula I where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula I are also provided.
    Type: Grant
    Filed: December 10, 2003
    Date of Patent: November 7, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Shaoqing Chen, Wendy Lea Corbett, Kevin Richard Guertin, Nancy-Ellen Haynes, Robert Francis Kester, Francis A. Mennona, Steven Gregory Mischke, Yimin Qian, Ramakanth Sarabu, Nathan Robert Scott, Kshitij Chhabilbhai Thakkar
  • Novel substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
    Publication number: 20040209943
    Abstract: The present invention relates to compounds of formula (I) 1
    Type: Application
    Filed: April 8, 2004
    Publication date: October 21, 2004
    Inventors: Shawn David Erickson, Paul Gillespie, Kevin Richard Guertin
  • 5-Substituted-six-membered heteroaromatic glucokinase activators
    Publication number: 20040147748
    Abstract: The present invention provides a compound according to formula I 1
    Type: Application
    Filed: December 10, 2003
    Publication date: July 29, 2004
    Inventors: Shaoqing Chen, Wendy Lea Corbett, Kevin Richard Guertin, Nancy-Ellen Haynes, Robert Francis Kester, Francis A. Mennona, Steven Gregory Mischke, Yimin Qian, Ramakanth Sarabu, Nathan Robert Scott, Kshitij Chhabilbhai Thakkar
  • Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors
    Patent number: 6642381
    Abstract: The invention relates to pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds which are useful for inhibiting protein tyrosine phosphatases, particularly PTP1B.
    Type: Grant
    Filed: December 10, 2002
    Date of Patent: November 4, 2003
    Assignee: Hoffman-La Roche Inc.
    Inventors: Kevin Richard Guertin, Lina Quattrocchio Setti
  • Pyrimido[5,4-e] [1,2,4]triazine-5, 7-diamine compounds as protein tyrosine phosphatase inhibitors
    Publication number: 20030153756
    Abstract: The invention relates to pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds which are useful for inhibiting protein tyrosine phosphatases, particularly PTP1B.
    Type: Application
    Filed: December 10, 2002
    Publication date: August 14, 2003
    Inventors: Kevin Richard Guertin, Lina Quattrocchio Setti